Vaginal ring adherence in sub-saharan Africa: Expulsion, removal, and perfect use

AIDS and Behavior

Volumn 16, Issue 7, 2012, Pages 1787-1798

  Montgomery, Elizabeth T ^a   Van Der Straten, A ^a,b   Cheng, H ^a   Wegner, L ^a   Masenga, G ^c   Von Mollendorf, C ^d   Bekker, L ^e   Ganesh, S ^f   Young, K ^g   Romano, J ^h   Nel, A ^g   Woodsong, C ^g  

^a RTI INTERNATIONAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Kiliminjaro Christian Medical Center   (Tanzania)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^g INTERNATIONAL PARTNERSHIP FOR MICROBICIDES   (United States)

^h NWJ Group LLC   (United States)

Author keywords

Adherence; Female controlled HIV prevention methods; Microbicide delivery; Sub Saharan Africa; Vaginal ring

Indexed keywords

TOPICAL ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; ETHNOLOGY; FEMALE; FEMALE CONTRACEPTIVE DEVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVAGINAL DRUG ADMINISTRATION; MEDICATION COMPLIANCE; MULTIVARIATE ANALYSIS; PSYCHOLOGICAL ASPECT; QUALITATIVE RESEARCH; RANDOMIZED CONTROLLED TRIAL; SOCIOECONOMICS; SOUTH AFRICA; STATISTICS; TANZANIA; UTILIZATION REVIEW;

ADMINISTRATION, INTRAVAGINAL; ADOLESCENT; ADULT; ANTI-INFECTIVE AGENTS, LOCAL; CONTRACEPTIVE DEVICES, FEMALE; CROSS-OVER STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; MULTIVARIATE ANALYSIS; QUALITATIVE RESEARCH; SOCIOECONOMIC FACTORS; SOUTH AFRICA; TANZANIA; YOUNG ADULT;

EID: 84868501023     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-012-0248-4     Document Type: Article

References (32)

1. UNAIDS. UNAIDS Reports on the Global AIDS Epidemic 2010. Available from http://www.unaids.org/globalreport/default.htm. Accessed 19 Dec 2011
2. Malcolm RK, Edwards KL, Kiser P, Romano J, Smith TJ. Advances in microbicide vaginal rings. Antiviral Res. 2010;88 (Suppl 1):S30-9
3. Nel A, Smythe S, Young K, Malcolm K, McCoy C, Rosenberg Z, et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr. 2009;51:416-23
4. Romano J, Variano B, Coplan P, Van Roey J, Douville K, Rosenberg Z, et al. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses. 2009;25(5):483-8
5. Karim QA, Karim SA, Frohlich J, Grobler A, Baxter C, Mansoor L, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-74
6. Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New Engl J Med. 2010. doi:10.1056/ NEJMoa1011205
7. Weiss RA. HIV receptors and the pathogenesis of AIDS. Science. 1996;272(5270):1885-6
8. Institute of Medicine. Methodological challenges in biomedical HIV prevention trials. Institute of Medicine. 2008. Available from: http://www.iom.edu/Reports/2008/Methodological-Challenges- in-Biomedical-HIV- Prevention-Trials.aspx. Accessed 19 Dec 2011
9. Microbicide trials network statement on decision to discontinue use of oral Tenofovir tablets in VOICE, a major HIV prevention study in women. Microbicide Trials Network. 2011
10. Microbicide trials network statement on decision to discontinue use of Tenofovir gel in VOICE, a major HIV prevention study in women. 2011
11. FHI statement on the FEM-PrEP HIV prevention study: FHI to initiate orderly closure of FEM-PrEP. FHI 2011
12. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. How well does PREP work? Unraveling the divergent results of PrEP trials for HIV prevention. AIDS 2012;26(7):F13-F9
13. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al., editors. The FEM-PrEP trial of emtricitabine/ tenofovir disoproxil fumarate (Truvada) among African Women. The 19th Conference on Retrovirus and Opportunistic Infections. Seattle; 5-8 March 2012
14. Hardy E, Hebling EM, Sousa MH, Almeida AF, Amaral E. Delivery of microbicides to the vagina: difficulties reported with the use of three devices, adherence to use and preferences. Contraception. 2007;76(2):126-31
15. de la Novák A, Loge C, Abetz L, van der Meulen EA. The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability. Contraception. 2003;67(3): 187-94
16. Dieben T, Roumen F, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol. 2002;100(3):585-93
17. Gilliam ML, Neustadt A, Kozloski M, Mistretta S, Tilmon S, Godfrey E. Adherence and acceptability of the contraceptive ring compared with the pill among students: a randomized controlled trial. Obstet Gynecol. 2010;115(3):503-10
18. Nel A, Young K, Romano J, Woodsong C, Montgomery E, Masenga G, et al. Safety and acceptability of silicone elastomer vaginal rings as potential microbicide delivery method in African Women. 18th Conference on Retroviruses and Opportunistic Infections. 2011(Paper #1004)
19. van der Straten A, Montgomery E, Cheng H, Wegner L, Masenga G, von Mollendorf C, et al. High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African Women. AIDS Behav. 2012
20. Nel A, Young K, Romano J, Woodsong C, van der Straten A, Masenga G, et al. Safety and acceptability of silicone elastomer vaginal rings as potential microbicide delivery method in African women. International partnership for microbicides; Silver Spring, MD, 2011
21. Simons-Rudolph A, Woodsong C, Koo H. Modeling the social context of microbicide use. Microbicide Q. 2008;6(4):1-11
22. Woodsong C, Alleman P. Sexual pleasure, gender power and microbicide acceptability in Zimbabwe and Malawi. AIDS Educ Prev. 2008;20(2):171-87
23. Sahin-Hodoglugil N, Montgomery E, Kacanek D, Morar N, Mtetwa S, Nkala B, et al. User experiences and acceptability attributes of the diaphragm and lubricant gel in an HIV prevention trial in Southern Africa: a theory based qualitative analysis (under review). 2010
24. Woodsong C, Simons-Rudolph A, Alleman P. A comprehensive and flexible conceptual framework for investigating acceptability in microbicide clinical trials (Poster Presentation). Microbicides. Delhi 2008
25. Montgomery ET, Blanchard K, Cheng H, Chipato T, de Bruyn G, Ramjee G, et al. Diaphragm and lubricant gel acceptance, skills and patterns of use among women in an effectiveness trial in Southern Africa. Eur J Contracept Reprod Health Care. 2009; 14(6):410-9
26. Montgomery ET, Woodsong C, Musara P, Cheng H, Chipato T, Moench TR, et al. An acceptability and safety study of the Duet®cervical barrier and gel delivery system in Zimbabwe. J Int AIDS Soc. 2010;13:30
27. Smith DJ, Wakasiaka S, Hoang TD, Bwayo JJ, Del Rio C, Priddy FH. An evaluation of intravaginal rings as a potential HIV prevention device in urban Kenya: behaviors and attitudes that might influence uptake within a high-risk population. J Womens Health (Larchmt). 2008;17(6):1025-34
28. Montgomery E, van der Straten A, Chidanyika A, Chipato T, Jaffar S, Padian N. The importance of male partner involvement for women's acceptability and adherence to female-initiated HIV prevention methods in Zimbabwe. AIDS Behav. 2010;epub ahead of print. doi:10.1007/s10461-010-9806-9
29. Tepe M, Mestad R, Secura G, Allsworth JE, Madden T, Peipert JF. Association between tampon use and choosing the contraceptive vaginal ring. Obstet Gynecol. 2010;115(4):735-9
30. Schafer J, Osborne L, Davis A, Westhoff C. Acceptability and satisfaction using Quick Start with the contraceptive vaginal ring versus an oral contraceptive. Contraception. 2006;73:488-92
31. Verhoeven CH, Dieben TO. The combined contraceptive vaginal ring, NuvaRing, and tampon co-usage. Contraception. 2004;69(3): 197-9
32. Madden T, Blumenthal P. Contraceptive vaginal ring. Clin Obstet Gynecol. 2007;50(4):878-85